Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from RXRX

Nvidia Dumped Recursion Pharmaceuticals Stock. Should You?

Nvidia sold its position in Recursion Pharmaceuticals, while others keep a measured outlook. Does this divergence signal risk or opportunity?

Cathie Wood Is Doubling Down on Recursion Pharmaceuticals Stock. Should You Buy RXRX Here?

Cathie Wood Is Doubling Down on Recursion Pharmaceuticals Stock. Should You Buy RXRX Here?

Cathie Wood is resolute on RXRX despite its slump. Should investors follow her lead into this AI-driven biotech bet now?

What's Going On With Recursion Pharmaceuticals Stock On Wednesday?

What's Going On With Recursion Pharmaceuticals Stock On Wednesday?

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Looking for the Next Big Pop? Here’s Why Recursion Pharmaceuticals (RXRX) Could Do a Dead-Cat Bounce

While Recursion Pharmaceuticals has struggled for traction this year, the elevated short interest of RXRX stock and a key quant signal imply a near-term lift.

Recursion Pharmaceuticals Reports Wider-Than-Expected Q2 Loss, Beats Revenue Estimates

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) shares are volatile on Tuesday following the release of the company’s second-quarter financial results. Here’s what you need to know.

Why Is Recursion Pharma Stock Surging On Monday?

In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood (vero_greenwood).

This Nvidia-Backed AI Stock Is Shrugging Off Market Pain Thanks to the FDA. Should You Buy Shares Now?

Recursion Pharmaceuticals stock rallied as FDA announces plans of using AI for drug testing. Is it too late to invest in RXRX shares?

inkl

Read news from The Economist, FT, and more,
with one subscription

Biotechs on the Brink: 2 Stocks With Huge Potential

Biotechs on the Brink: 2 Stocks With Huge Potential

BriaCell Therapeutics and Recursion Pharmaceuticals are two biotech firms that may be poised for success in 2025; risk-tolerant investors might keep an eye out.

1 AI Biotech Stock That Just Scored a Major Milestone

1 AI Biotech Stock That Just Scored a Major Milestone

Down over 85% from all-time highs, Recursion Pharmaceuticals is an AI-powered biotech company that aims to accelerate the drug discovery process.

AI Could Power Up These 2 Biotech Stocks

AI Could Power Up These 2 Biotech Stocks

AI is rapidly transforming the healthcare industry. Evolving companies such as Intuitive Surgical and Recursion Pharmaceuticals can capitalize on this opportunity.

Should You Buy the Dip in This AI-Driven Drug Stock?

Should You Buy the Dip in This AI-Driven Drug Stock?

Down 76% from all-time highs, is this AI-powered drug stock a good buy right now?

3 Small-Cap Stocks to Invest in AI Drug Development

3 Small-Cap Stocks to Invest in AI Drug Development

As AI continues to reshape the drug development landscape, here are three promising small-cap biotech stocks worth considering now.

1 AI Growth Stock With 54% Upside Potential

1 AI Growth Stock With 54% Upside Potential

Shares of Recursion Pharmaceuticals offer solid upside potential, given the company's trailblazing approach to drug discovery leveraging AI. Here’s a closer look at the biotech stock that has garnered investments from both AI chipmaker Nvidia and ARKK fund manager Cathie Wood.

Nvidia Just Invested $76 Million in 1 Cathie Wood Stock

Nvidia Just Invested $76 Million in 1 Cathie Wood Stock

Along with plowing cash into smaller AI chip stocks, Nvidia also made an outsized bet on this Utah-based biotech company that's a part of Wood's flagship ARKK fund.

Get all your
news in one place.

100’s of premium titles.
One news app.

Nvidia Just Invested $76 Billion in 1 Cathie Wood Stock

Along with plowing cash into smaller AI chip stocks, Nvidia also made an outsized bet on this Utah-based biotech company that's a part of Wood's flagship ARKK fund.

1 Cathie Wood Stock With Over 100% Upside, According to Analysts

This biotech stock under $10 is the newest addition to Cathie Wood's flagship ARKK fund - and Wall Street analysts have high hopes for the shares, too.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Intuitive Surgical

Recursion Pharmaceuticals

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

345,031 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play